5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.32▲ | 2.32▲ | 2.32▲ | 2.33▲ | 2.39▼ |
MA10 | 2.31▲ | 2.31▲ | 2.28▲ | 2.35▲ | 2.33▲ |
MA20 | 2.29▲ | 2.28▲ | 2.30▲ | 2.42▼ | 2.50▼ |
MA50 | 2.30▲ | 2.34▲ | 2.34▲ | 2.31▲ | 2.85▼ |
MA100 | 2.34▲ | 2.35▲ | 2.39▼ | 2.53▼ | 3.63▼ |
MA200 | 2.35▲ | 2.42▼ | 2.38▼ | 2.73▼ | 15.03▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.006▲ | 0.013▲ | 0.011▲ | -0.019▼ | 0.019▲ |
RSI | 66.288▲ | 60.102▲ | 58.505▲ | 49.747▼ | 44.774▼ |
STOCH | 50.833 | 81.261▲ | 83.990▲ | 31.106 | 57.044 |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -57.778 | -55.656 |
CCI | 126.838▲ | 99.454 | 127.171▲ | -67.309 | -21.151 |
Monday, June 16, 2025 07:02 AM
Analysts are estimating that VistaGen Therapeutics will report an earnings per share (EPS) of $-0.52. Anticipation surrounds VistaGen Therapeutics's announcement, with investors hoping to hear about ...
|
Saturday, June 07, 2025 02:05 PM
VISTAGEN THERAPEUTICS ($VTGN) is expected to release its quarterly earnings data on Monday, June 9th after market close, per Finnhub. Analysts are expecting revenue ...
|
Thursday, June 05, 2025 04:59 PM
SOUTH SAN FRANCISCO, Calif., June 02, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 2.25 | 2.37 | 2.25 | 2.37 | 147,335 |
13/06/25 | 2.29 | 2.36 | 2.18 | 2.21 | 160,343 |
12/06/25 | 2.35 | 2.38 | 2.29 | 2.315 | 106,005 |
11/06/25 | 2.40 | 2.4982 | 2.35 | 2.36 | 130,408 |
10/06/25 | 2.31 | 2.41 | 2.29 | 2.39 | 173,316 |
09/06/25 | 2.39 | 2.39 | 2.25 | 2.34 | 205,509 |
06/06/25 | 2.38 | 2.42 | 2.33 | 2.36 | 83,700 |
05/06/25 | 2.40 | 2.42 | 2.32 | 2.37 | 54,400 |
04/06/25 | 2.41 | 2.415 | 2.34 | 2.39 | 46,875 |
03/06/25 | 2.41 | 2.43 | 2.3367 | 2.39 | 95,468 |
|
|
||||
|
|
||||
|
|